Skip to main content

Advertisement

SpringerLink
Log in

Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?

  • Original
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract

Purpose

The need for continuous anticoagulation remains a significant drawback in continuous renal replacement therapy (CRRT), especially in patients with increased bleeding risk. Polyethyleneimine treatment of the AN69 membrane (AN69ST) reduces thrombogenicity through decreased contact activation and promotion of heparin binding. The aim of this study is to evaluate whether this membrane prolongs filter survival in CRRT without anticoagulation.

Methods

A single-center, prospective, randomized, double-blind controlled trial with cross-over design comparing filter survival with the AN69ST membrane and the original AN69 membrane in 39 patients treated with continuous venovenous hemofiltraton (CVVH) without additional heparin.

Results

Filter survival with the AN69ST membrane (n = 75) was 14.2 ± 8.2 h, which is not significantly different from the 13.3 ± 10.3 h for the original AN69 membrane (n = 76; p = 0.59). Limiting the analysis to those treatments that were interrupted for filter clotting yielded similar results: 14.4 ± 8.2 h for the AN69 ST membrane (n = 62) versus 14.1 ± 7.5 h for the original AN69 membrane (n = 56) (p = 0.93).

Conclusions

Compared with the original AN69 membrane, the surface-treated AN69ST membrane does not prolong filter survival during CVVH without systemic anticoagulation and with the CRRT settings used in this study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR (2006) Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 32:188–202

    Article  PubMed  CAS  Google Scholar 

  2. Oudemans-van Straaten HM (2010) Citrate anticoagulation for continuous renal replacement therapy in the critically ill. Blood Purif 29:191–196

    Article  PubMed  CAS  Google Scholar 

  3. Thomas M, Valette P, Mausset AL, Déjardin P (2000) High molecular weight kininogen adsorption on hemodialysis membranes: influence of pH and relationship with contact phase activation of blood plasma. influence of pre-treatment with poly(ethyleneimine). Int J Artif Organs 23:20–26

    PubMed  CAS  Google Scholar 

  4. Chanard J, Lavaud S, Paris B, Toure F, Rieu P, Renaux JL, Thomas M (2005) Assessment of heparin binding to the AN69 ST hemodialysis membrane: I Preclinical studies. ASAIO J 51:342–347

    Article  PubMed  CAS  Google Scholar 

  5. Lavaud S, Paris B, Maheut H, Randoux C, Renaux JL, Rieu P, Canard J (2005) Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J 51:348–351

    Article  PubMed  CAS  Google Scholar 

  6. Evenepoel P, Dejagere T, Verhamme P, Claes K, Kuypers D, Bammens B, Vanrenterghem Y (2007) Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis 49:642–649

    Article  PubMed  CAS  Google Scholar 

  7. Richtrova P, Rulcova K, Mares J, Reischig T (2010) Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect. Artif Organs 35:83–88

    Article  Google Scholar 

  8. Sagedal S, Witczak BJ, Osnes K, Hartmann A, Os I, Eikvar L, Klingenberg O, Brosstad F (2011) A heparin-coated dialysis filter (AN69 ST) does not reduce clotting during hemodialysis when compared to a conventional polysulfone filter (F × 8). Blood Purif 32:151–155

    Article  PubMed  CAS  Google Scholar 

  9. Brunet Ph, Frances J, Vacher-Coponat H, Jaubert D, Lebrun G, Gondouin B, Duval A, Berland Y (2011) Hemodialysis without heparin: a randomized, controlled, crossover study of two dialysis membranes (AN69ST and polysulfone F60). Int J Artif Organs 34:1165–1171

    Article  PubMed  CAS  Google Scholar 

  10. Burry LD, Tung DD, Hallett D, Bailie T, Carvalhana V, Lee D, Ramganesh S, Richardson R, Mehta S, Lapinsky SE (2009) Regional Citrate Anticoagulation for PrismaFlex Continuous Renal Replacement Therapy. Annals Pharmacother 43:1419–1425 (abstract)

    Article  CAS  Google Scholar 

  11. Xie W, Heidenreich S, Abbas S, Mann H (2009) Alteration of membrane properties in hemofilters during continuous hemofiltration (CVVH). ASAIO J 55:178 (abstract)

    Google Scholar 

  12. Xie WH, Heidenreich S, Vienken J, Mann H (2010) Shear stress in the hollow fibers and protein permeability during continuous hemofiltration. Int J Artif Organs 33:443 (abstract)

    Google Scholar 

  13. Kleger GR, Fässler E (2010) Can circuit lifetime be a quality indicator in continuous renal replacement therapy in the critically ill? Int J Artif Organs 33:139–146

    PubMed  Google Scholar 

  14. Lavaud S, Canivet E, Wuillai A, Maheut H, Randoux C, Bonnet JM, Renaux JL, Chanard J (2003) Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Nephrol Dial Transpl 18:2097–2104

    Article  CAS  Google Scholar 

  15. Chanard J, Lavaud S, Maheut H, Kazes I, Vitry F, Rieu P (2008) The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Nephrol Dial Transpl 23:2003–2009

    Article  CAS  Google Scholar 

  16. Kappelmayer J, Bernabei A, Edmunds LH Jr, Edgington TS, Colman RW (1993) Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 72:1075–1081

    Article  PubMed  CAS  Google Scholar 

  17. Tabuchi N, Shibamiya A, Koyama T, Fukuda T, Oeveren Wv W, Sunamori M (2003) Activated leukocytes adsorbed on the surface of an extracorporeal circuit. Artif Organs 27:591–594

    Article  PubMed  Google Scholar 

  18. Keuren JF, Wielders SJ, Willems GM, Morra M, Lindhout T (2002) Fibrinogen adsorption, platelet adhesion and thrombin generation at heparinized surfaces exposed to flowing blood. Thromb Haemost 87:742–747

    PubMed  CAS  Google Scholar 

  19. Zemanova P, Opatmy K, Vit L, Sefma F (2005) Tissue factor, its inhibitor, and the thrombogenicity of two new synthetic membranes. Artif Organs 29:651–657

    Article  PubMed  CAS  Google Scholar 

  20. Barstad RM, Hamers MJ, Møller AS, Sakariassen KS (1998) Monocyte procoagulant activity induced by adherence to an artificial surface is reduced by end-point immobilized heparin-coating of the surface. Thromb Haemost 79:302–305

    PubMed  CAS  Google Scholar 

  21. Semeraro F, Ammollo CT, Semeraro N, Colucci M (2009) Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. Haematologica 94:819–826

    Article  PubMed  CAS  Google Scholar 

  22. Levi M, van der Poll T, ten Cate H (2006) Tissue factor in infection and severe inflammation. Semin Thromb Hemost 32:33–39

    Article  PubMed  CAS  Google Scholar 

  23. Osterud B (1998) Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 9(Suppl 1):S9–S14

    PubMed  CAS  Google Scholar 

  24. Joannidis M, Oudemans-van Straaten HM (2007) Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 11:218

    Article  PubMed  Google Scholar 

  25. Young E, Prins M, Levine MN, Hirsh J (1992) Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 67:639–643

    PubMed  CAS  Google Scholar 

  26. Young E, Podor TJ, Venner T, Hirsh J (1997) Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 17:1568–1574

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

The authors report no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Intensive Care Medicine, University Hospital of the Catholic University Leuven, Herestraat 49, 3000, Leuven, Belgium

    Miet Schetz, Sophie Van Cromphaut, Jasperina Dubois & Greet Van den Berghe

Authors
  1. Miet Schetz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Van Cromphaut
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jasperina Dubois
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Greet Van den Berghe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miet Schetz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schetz, M., Van Cromphaut, S., Dubois, J. et al. Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?. Intensive Care Med 38, 1818–1825 (2012). https://doi.org/10.1007/s00134-012-2633-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-012-2633-x

Keywords

Search

Navigation